LAVA Therapeutics N.V.: Business Overview, Financials & Competitive Analysis
LAVA Therapeutics N.V. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Proprietary gamma-delta T cell platform with tier-1 pharma partnerships, but challenged by clinical setbacks and operational restructuring leading to acquisition. The company built a proprietary Gammabody® platform that big pharma—Johnson & Johnson and Pfizer—bet on despite reporting zero revenue in the first two quarters of 2025. However, the company.
What is LAVA Therapeutics N.V.'s industry? LAVA Therapeutics N.V. (lavatherapeutics.com) operates in Biotechnology - Clinical-Stage Immuno-Oncology. AskCyborg classifies LAVA Therapeutics N.V. under Biotechnology - Clinical-Stage Immuno-Oncology in its company registry.
LAVA Therapeutics is a clinical-stage immuno-oncology company focused on advancing its proprietary Gammabody® platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of so...
Cyborg Score thesis
Proprietary gamma-delta T cell platform with tier-1 pharma partnerships, but challenged by clinical setbacks and operational...
Read the full analyst-debate transcript →Get the Latest LAVA Therapeutics N.V. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeLAVA Therapeutics N.V. Overview
Pro stress-test →LAVA Therapeutics is a clinical-stage immuno-oncology company focused on advancing its proprietary Gammabody® platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid tumors and hematologic malignancies. The company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 T cell anti-tumor effector functions upon cross-linking to tumor-associated antigens.
Strategic Profile
Pro stress-test →LAVA Therapeutics was acquired by XOMA Royalty Corporation in November 2025. The company continues to enroll in the Phase 1 clinical study evaluating the safety and pharmacokinetics of LAVA-1266 in hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), and supports partnerships with Pfizer and Johnson and Johnson. LAVA's pipeline includes three internal and partnered clinical-stage bispecific gamma-delta T cell engagers including LAVA 1266, targeting CD123+ cancers; PF-08046052, targeting EGFR; and JNJ-89853413, targeting hematological cancers.
Competitive Landscape
Pro stress-test →LAVA competes in the immuno-oncology space with companies developing bispecific antibodies and T cell engagers. Key differentiators include its proprietary Gammabody platform targeting gamma-delta T cells (less explored than alpha-beta T cells) and partnerships with major pharma including Pfizer and Johnson & Johnson. Competitors include broader immuno-oncology players focused on CAR-T, TCR-engineered, and conventional bispecific approaches.
Industry Context
LAVA Therapeutics N.V. operates in Biotechnology - Clinical-Stage Immuno-Oncology.
Key facts
Founded: 2016 · Headquarters: Utrecht, Netherlands · Employees: 10 (post-acquisition) · Revenue: $11.98M (2024)